
Where Is Psilocybin Legal? US Laws and State Programs in 2026
Federal law: still Schedule I
At the federal level, psilocybin is a Schedule I controlled substance — illegal to possess outside of approved research. But the federal posture is softening in practice. In April 2026, following a White House executive order on serious mental illness, the FDA issued national priority vouchers to companies developing psilocybin for treatment-resistant depression and major depressive disorder, dramatically shortening review timelines.
The agency has also finalized its formal guidance for psychedelic clinical trials, giving drug developers a clear regulatory path for the first time.
State-regulated access
- Oregon was first: licensed service centers have offered supervised psilocybin sessions to adults 21 and over since 2023, no diagnosis required.
- Colorado followed, with its regulated healing centers opening under a voter-approved framework.
- Several other states have active bills, pilot programs or task forces, and many cities have made enforcement a low priority.
What FDA approval would change
If a Phase 3 trial succeeds and the FDA approves a psilocybin product — analysts quoted in Nature increasingly describe approval as a matter of when, not if — the drug would be rescheduled and available by prescription, likely through a restricted distribution program similar to Spravato (esketamine). That would not make mushrooms legal; it would create a medical channel for a specific, manufactured product.
What this means for you
- Buying or possessing mushrooms remains a crime in most of the country.
- Clinical trials are the only legal access route in most states — search ClinicalTrials.gov for recruiting studies.
- Oregon and Colorado programs are open to out-of-state visitors who meet their requirements.
This article is for information only and is not legal advice. Laws change quickly; check your state''s current rules.
Written by
Psilocybin News Editorial Team
The Psilocybin News editorial team covers psychedelic science, clinical research and policy, translating peer-reviewed evidence into clear, accurate reporting for patients, families and professionals.
PreviousAntidepressants and Psilocybin Trials: Why Medication Changes Need Medical Oversight
NextResponse, Remission, Relapse: Decoding Psilocybin Depression Results


